S
udden cardiac death produces a major worldwide public health burden, with an estimated annual occurrence ranging from 180 000 to 450 000 in the United States 1 and as many as 3.7 million deaths worldwide. 2 Sudden death in the young has a devastating and profound societal impact with ≈2000 to 5000 young people between 1 and 35 years of age experiencing sudden cardiac death yearly in the United States alone. 3 Potentially lethal cardiac arrhythmia syndromes, such as long QT syndrome (LQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT), and idiopathic ventricular fibrillation underlie a significant portion of sudden death in the young.
Recently, a few small cohort studies and case reports have identified TRDN-encoded cardiac triadin as an underlying cause for some patients diagnosed originally as LQTS, CPVT, or idiopathic ventricular fibrillation. [4] [5] [6] [7] [8] In 2012, triadin null mutations were first published as an underlying cause for recessively inherited arrhythmogenic disease when 2 out of 97 (2%) patients diagnosed with CPVT, yet genotype negative for RYR2 and CASQ2, were discovered to have either homozygous or compound heterozygous triadin null mutations. 4 Three subsequent case reports have also identified triadin null mutations in patients originally diagnosed with CPVT or idiopathic ventricular fibrillation. [5] [6] [7] In 2015, Altmann et al 8 discovered either homozygous or compound heterozygous frameshift mutations in TRDN to be the underlying cause of disease in 5 patients diagnosed originally with genetically elusive LQTS. These subjects had a common electrocardiographic and clinical phenotype with atypical feature of both LQTS and CPVT. Consequently, triadin knockout syndrome (TKOS) was coined rather than TRDN-mediated LQTS/LQT17 or TRDN-mediated CPVT/CPVT5. 8 Remarkably, all 5 patients displayed either consistent or transient QT prolongation, exhibited extensive T-wave inversions (TWI) in precordial leads V 1 through V 4 , and experienced severe disease expression of exerciseinduced sudden cardiac arrest (SCA) in early childhood, with most experiencing recurrent breakthrough cardiac events (BCEs), despite aggressive therapy. Additionally, 2 of the 5 patients displayed mild skeletal muscle weakness. 8 Given the potentially lethal nature of this syndrome, we set out to better define the phenotype and treatment outcomes of patients with TKOS through the establishment of the International Triadin Knockout Syndrome Registry (ITKOSR).
METHODS
To prevent the reidentification of patients included in this study, individual patient data will not be made available to other researchers. This study was approved by the Mayo Clinic Institutional Review Board which included a waiver for informed patient consent. The detailed methods are included in the Data Supplement.
RESULTS

Patient Demographics
Overall, we identified 21 patients from 16 unrelated families that met the criteria for inclusion into the ITKOSR (Tables 1 and 2) . Of the 21 patients, 14 have been described previously in the literature. [4] [5] [6] [7] [8] Overall, there were 11 (52%) males and 10 (48%) females. The average age of enrollment into the registry was 18±14 years of age (ranging from 3 to 45 years). Patients came from a variety of ethnic backgrounds including white (8/21, 38%), Indian, (4, 19%), Latino (3, 14%), African (2, 9%), and Arabic (2, 9%), along with 2 (9%) patients who were half white and half African (Table 2) . Before their TKOS diagnosis, patients were diagnosed with either LQTS (8/21, 38%), CPVT (7, 33%), idiopathic ventricular fibrillation (4, 19%) , exercise-induced syncope (1, 5%), or unexplained sudden cardiac death (1, 5%; Figure I in the Data Supplement).
Genetics
All patients enrolled in the ITKOSR have either homozygous (12/21, 57%) or compound heterozygous (9/21, 43%) triadin null variants (Table 3) . We identified 13 unique pathogenic variants or likely pathogenic variants in TRDN (Figure 1 ; Table I in the Data Supplement). Of these unique variants, 7 were discovered in previously published cases of TKOS, 4-8 whereas 6 are being reported here for the first time. The vast majority of these variants were either frameshift (6, 46%), nonsense (2, 15%), or splice site-altering (2, 15%) variants that lead to an early stop codon and nonsense-mediated decay. Four of the pathogenic variants (p.D18fs*13 [ (Figure 1 ; Table I in the Data Supplement). The transmembrane domain residing p.T59R missense variant has been characterized previously and shown to result in an unstable protein that undergoes proteasomal degradation. 4 Presumably, the p.T59M missense variant occurring at the same amino acid residue as p.T59R also produces an unstable protein that undergoes proteasomal degradation and ultimately results in a null allele. The homozygous deletion of exon 2 which encodes for most of the N terminus and all of the transmembrane domain of triadin ( Figure 1 ) was identified in a single patient and recently reported by O'Callaghan et al.
Symptoms
Overall, 20 out of 21 (95%) patients were symptomatic, having had at least 1 cardiac event. Patients who had a recorded date of first cardiac event (18, 86%) presented at a young age, with their first event occurring at an average age of 3±2 years (Table 1) . Additionally, 83% of symptomatic patients presented by age 5 years, and all by 10 years of age. Syncope was the sentinel event in 5 (24%) patients, whereas 15 (71%) patients presented initially with SCA. However, 2 of the 5 patients who presented initially with syncope went on to have an SCA. Thus, 17 out of 21 (81%) patients have had an SCA (Tables 1 and 2 ).
The most common trigger was physical exertion which was associated with at least one cardiac event in 17 of the 21 (81%) patients. Other triggers included auditory stimuli, fear, and sleep. However, a large number of events were not associated with a specific trigger. In addition to their severe cardiac symptoms, 6 (29%) patients also presented with mild skeletal myopathy or slight proximal muscle weakness (Tables 1 and 2 ). Currently, 19 patients are still living, whereas 2 (patients no. 12 and no. 17, Table 2 ) have died after cardiac events.
Clinical Evaluation
All 19 surviving TKOS patients have had at least one 12-lead ECG. Of these, 10 patients (53%) exhibited a heart rate corrected QT interval (QTc) >480 ms on at least 1 ECG. Although the QT prolongation has been transient in 9 of the 10 patients, 1 patient does manifest a consistently prolonged QTc (patient no. 21, Table 2 ). Furthermore, 16 out of 19 (84%) surviving patients exhibit TWIs, of which 13 (68%) have TWIs in the precordial leads with the majority showing them in leads V 1 through V 3 or V 1 through V 4 (Tables 1 and 2) as shown in Figure 2A and Figure II in the Data Supplement.
All 16 patients tested had a normal echocardiogram suggesting a structurally normal heart (Tables 1 and  2) . Of the 9 patients that had an exercise stress test, 8 (89%) exhibited ventricular ectopy at an average onset heart rate of 108±24 bpm ( Table 1 ). The extent of exercise-induced ectopy seen in these patients was premature ventricular contractions in isolation, bigeminy, couplets, and triplets ( Figure 2B ; Table 2 ). None of the patients had either nonsustained ventricular tachycardia or bidirectional ventricular tachycardia.
Treatment
All 19 surviving patients are being treated with β-blocker therapy. The vast majority are currently on either nadolol (14, 74%) or propranolol (4, 21%), whereas 1 patient (5%) is being treated with Bisoprolol and 1 patient (5%) with metoprolol. In addition to β-blocker therapy, 6 (32%) patients have had a sodium (flecainide, n=5; mexiletine, n=1) or calcium (verapamil, n=1) channel blocker added to their treatment regimen. Left cardiac sympathetic denervation (LCSD) was completed in 9 (47%) patients, and 3 (15%) have also undergone a subsequent right cardiac sympathetic denervation (Table 1) .
A total of 14 (74%) patients have undergone device implantation. Thirteen (68%) have had an implantable cardioverter defibrillator implanted, and 1 patient (5%) Values are n (%) or mean±SD. BCE indicates breakthrough cardiac event; ICD, implantable cardioverter defibrillator; LCSD, left cardiac sympathetic denervation; QTc, corrected QT interval; RCSD, right cardiac sympathetic denervation; and TKOS, triadin knockout syndrome. underwent placement of a permanent pacemaker to allow for increased β-blocker dose (Table 1) .
Outcomes
Despite these various treatment strategies, 14 out of 19 (74%) surviving TKOS patients have had on-therapy BCEs. In fact, all but one of these patients (patient no. 19) has had >1 BCE, and 5 (26%) have had >5 BCEs ( Table 1 ).
The majority of TKOS patients have not only had multiple BCEs but also have experienced those events while on different combinations of therapy. Most surviving patients (17, 89%) were initially treated with either β-blocker ther- 
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Reference numbers indicate where that TKOS patient was first published. PVC indicates premature ventricular contraction; QTc, corrected QT interval; SCA, sudden cardiac arrest; and TKOS, triadin knockout syndrome. apy alone or in combination with a sodium or calcium channel blocker (drug therapy). While on drug therapy alone, 12/17 (71%) patients had at least 1 on-prescription therapy BCE ( Figure 3A) . These patients had anywhere from 1 to >10 BCEs. Among these 17 patients, the exact duration of follow-up was available for 14. Over a total of 76 years of follow-up, these patients experienced 53 BCEs for a yearly event rate of 0.70 BCEs/y ( Figure 3B ). Compliance issues may have played a role in a small number of these events. However, the vast majority of patients have been compliant with their pharmacological therapy.
After having a BCE, 6 patients went on to have an LCSD. Additionally, 2 patients (patients no. 6 and no. 14) were initially treated with drug therapy and LCSD. Despite the use of drug therapy and LCSD, these 8 (100%) patients all experienced BCEs (ranging from 1 to 3 events each; Figure 3A ). Among these 8 patients, follow-up data were available for 7 patients where 14 BCEs have occurred over 59 follow-up years, yielding a yearly event rate of 0.24 BCEs/y ( Figure 3B ). Two patients treated with drug therapy and LCSD also underwent right cardiac sympathetic denervation (patients no. 5 and no. 18), and 1 patient went straight from drug therapy to bilateral denervation (patient no. 19, Figure 3A) . To this point, 1 of the 3 (33%) patients treated with drug therapy plus LCSD and right cardiac sympathetic denervation has experienced BCEs ( Figure 3A) .
Based on the 12-lead ECG yielding their longest recorded QTc, it is noteworthy that patients with a BCE on average have a significantly longer QTc (487±25 ms, n=14) than those that have not had any BCEs (429±15 ms, n=5; P<0.0001; Figure 4 ).
DISCUSSION
Since 2012, when mutations in TRDN were first discovered to be an underlying cause of disease, 4 only a small number of reports have been put forward describing what we now refer to as TKOS. [5] [6] [7] [8] Similar to what has previously been established for LQTS and other arrhythmia syndromes, 9 we set out to collect comprehensive clinical data from a larger number of TKOS patients through an international registry to better understand the natural history, clinical features, and treatment outcomes of patients with this potentially lethal disease. To do this, we have established the ITKOSR and now present the first comprehensive study of the clinical phenotype and treatment outcomes of the first 21 patients enrolled in the ITKOSR.
Triadin is a critical protein within the cardiac calcium release unit complex where the L-type calcium channel (LTCC) is juxtaposed to the RyR2 (type 2 ryanodine receptor) calcium release channel on the junctional sarcoplasmic reticulum. 10, 11 This complex is responsible for mediating calcium sensing and proper excitationcontraction coupling in the heart. Triadin is known to bind multiple proteins within the calcium release unit including RyR2, Casq2 (calsequestrin 2) and Jph2 (junctophilin 2) and helps mediate proper calcium release from the sarcoplasmic reticulum through RyR2, as well as structural stabilization of the calcium release unit. 11, 12 The loss of triadin because of either homozygous or compound heterozygous null mutations leads to a particularly malignant and potentially lethal phenotype.
All but one of the patients in the registry (95%) has had at least 1 cardiac event. Although this rate is in itself extremely high, what is particularly concerning is that 81% of TKOS patients have experienced SCA. This rate is comparable to even the most malignant arrhythmia syndromes, such as Jervell and Lange-Nielsen syndrome, 13 Timothy syndrome, 14 and the calmodulinopathies (Table 4) . 18 Similar to these other malignant arrhythmia syndromes, TKOS patients present at a young age, usually before 5 years of age, which is much younger than most patients with LQTS or CPVT (Table 4). However, it should be noted that we cannot yet exclude the possibility that the severity of these cases is due in part to the fact that these are the initial cases of TKOS to be described and that, with time, milder cases may be diagnosed as has been the case with most other arrhythmia disorders. 23 Additionally, similar to other distinct arrhythmia syndromes that display noncardiac symptoms, such as JLNS, 13 TS, 14 and the calmodulinopathies, 18 29% of TKOS patients exhibit a mild skeletal myopathy or slight proximal muscle weakness (Table 4) . Alternative splicing of triadin mRNA results in tissue-specific isoforms of triadin found in both cardiac and skeletal muscle. [24] [25] [26] Because these different isoforms are homologous up to amino acid 264, 27 all of the mutations discovered to date resulting in cardiac triadin null status also re- Depicted is a schematic representation of TRDN-encoded cardiac triadin with all 13 of the known TKOS-causative variants. Each white dot represents the location of a corresponding pathogenic variant. The large bracket depicts the region of the protein that is missing because of the deletion of exon 2. The KEKE domain is the region known to be responsible for the interaction and binding of both calsequestrin and RyR2 (amino acids 210-224). SR indicates sarcoplasmic reticulum. sult in patients being skeletal muscle triadin null. 28 Why more TKOS patients do not display a skeletal phenotype remains unknown, but it is possible that we are underestimating the number of patients with a skeletal myopathy because of the fact that the phenotype is mild (at least as ascertained by genetic cardiologists) and most of these patients have not been evaluated by a neuromuscular specialist.
TKOS patients also show several interesting features on their ECG. Over 50% of TKOS patients exhibit QTc prolongation of >480 ms. Because this QT prolongation was only transiently observed in 90% of these patients, it Figure 4 is patient no. 1 in Table 2 . The first treatment listed for each patient represents their initial treatment strategy. The following number is the number of breakthrough cardiac events (BCEs) that the patient had while on that specific treatment strategy. This is then the same for each subsequent treatment listed. The last treatment listed for a patient is their current treatment strategy. The symbols in the right-hand column represent whether that patient has been implanted with a device (+, implantable cardioverter defibrillator; *, pacemaker; −, no device). For example, patient no. 7 was initiated on drug therapy and had 2 BCEs. Patient no. 7 then underwent left cardiac sympathetic denervation (LCSD) and had 3 more BCEs and is currently being treated with drug therapy and LCSD. This patient also has an implantable cardioverter defibrillator. B, The yearly event rate was calculated and expressed as events per follow-up year for patients with exact follow up time available on either drug therapy (0.70 BCEs/y, n=14) or drug therapy and LCSD (0.24 BCEs/y, n=7). DRUG denotes β-blocker or β-blocker+sodium/calcium channel blocker. RCSD indicates right cardiac sympathetic denervation. may be important for clinicians treating TKOS patients to collect serial ECGs. Interestingly, based on their longest QTc on record, TKOS patients that have experienced BCE had a significantly longer QTc than TKOS patients that have not broken through their therapy. Whether QTc is surrogate marker for those patients at greatest risk for experiencing a BCE remains to be determined. Our cohort as a whole displays an average QTc of 472 ms which is similar to previously published cohorts of patients with LQT1-3 [15] [16] [17] and is significantly longer than what has been observed in cohorts of patients with CPVT (Table 4). 20, 21 Conversely, 89% of TKOS patients exhibit induced ectopy at peak exercise on stress testing which is known to be a hallmark feature of CPVT [19] [20] [21] [22] and is rarely, if ever, observed in patients with LQTS (Table 4) .
Another common ECG feature among TKOS patients is the presence of extensive TWIs in the precordial leads. Although TWIs in the precordial leads can be common during childhood in healthy subjects, 29 the consistent extension of these inversions into leads V 3 , and especially V 4 and V 5 , represents an abnormal ECG phenotype. Whether or not TWIs continue to be present into adulthood remains to be seen, but when combined with other clinical features of TKOS, TWIs could serve as a distinct diagnostic criterion that separates TKOS from other arrhythmia syndromes.
Despite the fact that patients with triadin null status have been diagnosed previously with a variety of cardiac arrhythmia disorders, this clinical data provides substantial evidence suggesting that these patients do not have typical LQTS or CPVT, but instead suffer from a distinct overlap disorder that displays clinical features of multiple arrhythmia syndromes, as well as features unique to TKOS.
Multiple studies that have been completed in TKO mice also corroborate these findings. 30, 31 In mice, ablation of triadin causes perturbations in the structure of the calcium release unit and a loss of colocalization of the LTCC to RyR2 leading to increased sarcoplasmic reticulum calcium load and impaired LTCC inactivation which in turn causes both ventricular arrhythmias and decreased muscle strength. 30, 31 Therefore, it is hypothesized that in TKOS patients, sarcoplasmic reticulum calcium overload could be leading to delayed afterdepolarizations similar to CPVT, and delayed LTCC inactivation could cause a prolonged action potential and early afterdepolarizations, both of which are precursors of ventricular arrhythmias. 12 However, the definitive mechanism by which loss of triadin leads to such a severe patient phenotype has yet to be defined by characterization in a human-specific model.
It has also become clear from our clinical data that the treatment strategies which are currently available are not adequate to effectively manage patients with TKOS. β-blockers, which are highly effective in treating patients with LQTS or CPVT, 32, 33 failed to prevent cardiac events in 71% of TKOS patients. Additionally, whereas some patients have remained event free on combination β-blocker and flecainide therapy, which has been shown both clinically and experimentally to improve arrhythmia control in patients with CPVT, 34, 35 others who have been treated with either flecainide or mexiletine have gone on to have multiple BCEs. One patient is currently being treated with the calcium channel blocker verapamil along with β-blocker and flecainide. Although it is difficult to draw any conclusions about the therapeutic potential of calcium channel blockers in TKOS from this single patient, these drugs do provide a potential alternative when considering the proposed mechanism of delayed LTCC inactivation. 8, 30 However, the effectiveness of drugs, such as verapamil or nifedipine, may be limited because of the fact that they are known to target peak calcium current as opposed to LTCC inactivation.
Furthermore, despite that LCSD is known to be an effective treatment for patients with multiple arrhythmia syndromes, 36, 37 every TKOS patient who underwent an LCSD experienced at least 1 post-LCSD BCE. However, the rate at which these patients experienced BCEs was reduced compared with drug therapy alone. Although the addition of a right cardiac sympathetic denervation could be an effective treatment strategy for some patients with TKOS, the current evidence is limited to fully support this.
This data makes clear the refractory nature of TKOS to conventional treatment and highlights the urgent need for novel therapies to treat this severe and potentially life-threatening disease. We surmise that a potential therapeutic option could be protein replacement using gene therapy. Because these patients are natural knockouts for triadin, TKOS serves as an ideal candidate for protein replacement treatment using adeno-associated virus serotype 9-based delivery of the normal cardiac triadin isoform. 38, 39 Introducing normal cardiac triadin into the TKOS patient's cardiomyocytes could correct the abnormal arrhythmogenic phenotype and potentially cure the patient of their disease. In fact, this type of approach has previously been shown to be effective in treating recessively inherited, CASQ2-mediated CPVT2 in both mice and human patient-specific induced pluripotent stem cell-derived cardiomyocytes using adeno-associated virus serotype 9 delivery of WT-CASQ2. [40] [41] [42] Therefore, as we seek to better care for patients experiencing this severe and treatment-refractory disease, we highly encourage their continued enrollment into the ITKOSR to better understand TKOS and to ready a well-characterized cohort for future TRDN gene therapy trials.
